



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/645, 31/485, 31/42, 31/135, 31/55, 31/495</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/50044</p> <p>(43) International Publication Date: 12 November 1998 (12.11.98)</p>
<p>(21) International Application Number: PCT/US98/09253</p> <p>(22) International Filing Date: 6 May 1998 (06.05.98)</p> <p>(30) Priority Data: 60/045,900 7 May 1997 (07.05.97) US</p> <p>(71) Applicant (for all designated States except US): ALGOS PHARMACEUTICAL CORPORATION [US/US]; Collingwood Plaza, 4900 Route 33, Neptune, NJ 07753 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): CARUSO, Frank, S. [US/US]; 2 Bowling Green, Colts Neck, NJ 07722 (US).</p> <p>(74) Agents: DILWORTH, Peter, G. et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN</p>		
<p>(57) Abstract</p> <p>The neuropathic pain alleviating effectiveness of an antidepressant is significantly potentiated by administering the antidepressant prior to, with or following the administration of a nontoxic NMDA receptor antagonist.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR
ANTAGONIST, FOR TREATING NEUROPATHIC PAIN

BACKGROUND OF THE INVENTION

This invention relates to a composition and method for alleviating
neuropathic pain. More particularly, this invention is directed to such a composition
10 and method in which an antidepressant is combined with a nontoxic antagonist, or
blocker, for the N-methyl-D-aspartate (NMDA) receptor.

Neuropathic pain is pain that is due to functional abnormalities of the
nervous system. Fields, "Pain", McGraw-Hill, Inc. (1987), pp. 133 et seq. There are
a variety of possible mechanisms by which nerve dysfunction can cause neuropathic
15 pain: hyperactivity in primary afferent or central nervous system (CNS) nociceptive
neurons, loss of central inhibitory connections, and increased activity in sympathetic
efferents. Neuropathic pain typically occurs following injury to elements of the
nervous system involved in nociception, such as peripheral nerve injury, in which the
lesions deafferent the nociceptive pathway, the resultant pain sometimes being referred
20 to deafferentation pain. Neuropathic pain is much more likely to occur with peripheral
than with central nervous system damage. Examples of causes of painful nerve injury
are: accidental trauma, tumors, cervical or lumbar spine disease, and surgical
procedures. These injuries usually involve one or two peripheral nerves or nerve
roots, and the pain is felt in the body region normally innervated by the damaged
25 nerves. Additionally, there are also toxic, metabolic, and hereditary causes of painful
polyneuropathies, e.g., alcohol abuse, diabetes mellitus and toxicity due to cancer
chemotherapy. These tend to be symmetrical and are most severe on the distal limbs.

U.S. Patent No. 5,352,683 discloses a method for the treatment of chronic pain, inclusive of neuropathic pain, by administration of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan. However, there is no mention in this patent of combining a nontoxic NMDA receptor antagonist with an antidepressant for the treatment of neuropathic pain.

SUMMARY OF THE INVENTION

In accordance with the present invention, a therapeutic composition for alleviating neuropathic pain is provided which comprises at least one antidepressant in an amount sufficient to alleviate neuropathic pain and at least one nontoxic N-methyl-D-aspartate receptor antagonist in an amount sufficient to potentiate the neuropathic pain-alleviating activity of the antidepressant.

Further in accordance with the present invention, a method of alleviating neuropathic pain is provided which comprises coadministering to a mammal exhibiting neuropathic pain at least one antidepressant in an amount sufficient to alleviate neuropathic pain and at least one nontoxic N-methyl-D-aspartate receptor antagonist in an amount sufficient to potentiate the neuropathic pain-alleviating activity of the antidepressant.

The term "N-methyl-D-aspartate receptor" shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the glycine-binding site, the phenylcyclidine (PCP)-binding site, etc., as well as the NMDA channel. Thus, the invention herein contemplates the use of nontoxic substances that block an NMDA receptor binding site, e.g., dextromethorphan, or block the NMDA channel, e.g., a source of magnesium such as magnesium sulfate.

The term "nontoxic" as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United

States Food and Drug Administration ("FDA") for administration to humans or, in keeping with established regulatory criteria and practice, is susceptible to approval by the FDA for administration to humans. The term "nontoxic" is also used herein to distinguish the NMDA receptor antagonists, or blockers, that are useful in the practice
5 of the present invention from NMDA receptor antagonists such as MK 801 (the compound 5-methyl-10,11-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine), CPP (the compound 3-[2-carboxypiperazin-4-yl] propyl-1-phosphonic acid) and PCP (the compound 1-(1-phenylcyclohexyl)piperidine) whose toxicities effectively preclude their therapeutic use.

10 The terms "potentiate" and "potentiating" are used herein in their art-recognized sense, i.e., as referring to a significant increase in the level of neuropathic pain-alleviating activity for the combination of antidepressant and nontoxic NMDA receptor antagonist compared with that which could have been expected based on the neuropathic pain-alleviating activities of the antidepressant and nontoxic NMDA
15 receptor antagonist administered alone.

 The expression "neuropathic pain-alleviating" shall be understood herein to include the expressions "neuropathic pain-suppressing" and "neuropathic pain-inhibiting" as the invention is applicable to the alleviation of existing neuropathic pain as well as the suppression or inhibition of neuropathic pain which would otherwise
20 ensue from an imminent neuropathic pain-causing event.

 The expression "neuropathic pain-alleviating amount" as applied to the antidepressant employed in the therapeutic composition and method of this invention shall be understood to mean an amount of antidepressant which when administered by itself or in combination with the nontoxic NMDA receptor antagonist provides
25 significant neuropathic pain-alleviating activity.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Any of the known and conventional neuropathic pain-alleviating antidepressants can be used herein. For extensive listings of antidepressants, see, e.g., Goodman and Gilman's "The Pharmaceutical Basis Of Therapeutics", 8th ed., McGraw-Hill, Inc. (1990), pp. 405-414, and "Remington's Pharmaceutical Sciences", 17th ed., Mack Publishing Company (1985), pp. 1093-1098. Specific neuropathic pain-alleviating antidepressants that can be used herein include tricyclic antidepressants such as imipramine hydrochloride, imipramine pamoate, 2-chloroimipramine, amitriptyline hydrochloride, amoxapine, desipramine hydrochloride, doxepin hydrochloride, protriptyline hydrochloride, trimipramine maleate, nortriptyline hydrochloride, clomipramine hydrochloride, and the like; tetracyclic antidepressants such as maprotiline hydrochloride, and the like; monoamine oxidase (MAO) inhibitors such as phenelzine sulfate, isocarboxazid, tranylcypromine sulfate, and the like; serotonin uptake inhibitors such as paroxetine hydrochloride, fluoxetine hydrochloride, trazodone hydrochloride, citalopram, cis-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine such as sertraline hydrochloride, trans-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine, aryloxy indanamine, and the like; and, other antidepressants such as bupropion hydrochloride and benactyzine hydrochloride.

Among the nontoxic substances that block the NMDA receptor and as such are useful for potentiating the neuropathic pain-alleviating activity of the antidepressant in accordance with this invention are dextromethorphan ((+)-3-hydroxy-N-methylmorphinan), its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), amantadine (1-amino adamantine), memantine (3,5 dimethylaminoadamantone), their mixtures and their pharmaceutically acceptable salts. Other useful nontoxic substances that block the NMDA receptor include pyrroloquinoline quinone, 4-hydroxy-2(1H)-

quinolone derivatives and cis-4-(phosphono-methyl)-2-piperidinecarboxylic acid. Of the foregoing nontoxic substances that block the NMDA receptor, dextromethorphan is preferred due to its ready availability and its established use in over-the-counter medications where it functions as a cough suppressant.

5 The antidepressant must be present in a neuropathic pain-alleviating amount. Such an amount can correspond to the recommended adult human dosage level for a particular antidepressant when administered by itself or it can be less than this amount provided that in combination with the nontoxic NMDA receptor antagonist, significant neuropathic pain-alleviating activity is achieved. The NMDA receptor
10 antagonist must be present at a level sufficient to potentiate the neuropathic pain-alleviating effectiveness of the antidepressant. Specific dosage levels for the antidepressants that can be used herein are given, inter alia, in the "Physicians' Desk Reference", 1996 Edition (Medical Economics Data Production Company, Montvale, NJ) as well as in other reference works including Goodman and Gilman's "The
15 Pharmaceutical Basis of Therapeutics" and "Remington's Pharmaceutical Sciences" both of which as referred to above. Given the wide variation in dosage level of the antidepressant which depends to a large extent on the specific antidepressant being administered, there can similarly be a wide variation in the dosage level of the NMDA receptor antagonist. These amounts can be determined for a particular drug
20 combination employing routine experimental testing. For example, in the case of the tricyclic antidepressant imipramine hydrochloride and the nontoxic NMDA receptor blocker dextromethorphan, dosages of from about 50 to about 360 mg/day of the former coadministered with from about 30 to about 120 mg/day of the latter will usually provide acceptable results.

25

When the nontoxic NMDA receptor antagonist selected for use herein is dextromethorphan, dextrorphan or sale thereof, the antidepressant drug must be other than a monoamine oxidase inhibitor since antidepressants of this type are contraindicated for these NMDA receptor antagonists.

5 While the neuropathic pain-alleviating antidepressant and the potentiating nontoxic NMDA receptor antagonist need not be administered together, they must both be present in the patient at effective levels at the same time. While it is within the scope of the invention to separately administer the antidepressant and the nontoxic NMDA receptor antagonist, as a matter of convenience, it is preferred that these drugs
10 be coadministered in a single dosage form. All modes of administrations are contemplated, e.g., orally, rectally, parenterally, nasally, topically or by intravenous or intramuscular injection.

A therapeutic composition containing the antidepressant and nontoxic NMDA receptor antagonist will ordinarily be formulated with one or more
15 pharmaceutically acceptable ingredients in accordance with known and established practice. Thus, the composition can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as tablets or hard capsules wherein the pharmacologically active ingredients are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin
20 capsules wherein the active ingredients are mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.

Aqueous suspensions can include pharmaceutically acceptable excipients such as suspending agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth
25 and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g.,

polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monooleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, e.g., ethyl-or-n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.

10 In addition to the antidepressant and nontoxic NMDA receptor antagonist, the therapeutic composition herein can optionally contain at least one other pharmacologically active substance e.g., an antianxiety agent such as meprobamate and benzodiazepines, e.g., chlordiazepoxide, diazepam, oxazepam, clorazepate, lorazepam, prazepam, alprazolam, halazepam, clonazepam and the like; an antipsychotic agent
15 such as phenothiazines, e.g., perphenazine, chlorpromazine hydrochloride, triflupromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, fluphenazine enanthate, fluphenazine decanoate, trifluoperazine hydrochloride and the like; a non-narcotic analgesic such as tramadol, acetaminophen, aspirin, diclofenac, diflusal, etodolac,
20 fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, zomepirac and the like; or a narcotic analgesic such as codeine, dihydrocodeine, hydrocodone, levorphanol, morphine, oxycodone, and the like.

EXAMPLES 1-46

The following unit dosage forms are illustrative of the neuropathic pain-alleviating therapeutic combinations in accordance with the present invention:

<u>Example</u>	<u>Dosage Form</u>	<u>Antidepressant Drug (mg)</u>	<u>Nontoxic NMDA Receptor Blocker (mg)</u>	<u>Active Additional Component(s) (mg)</u>
5 1	capsule	chlomipramine	dextromethorphan	
10		hydrochloride (25)	hydrobromide (30)	
2	capsule	chlomipramine hydrochloride (50)	dextromethorphan hydrobromide (30)	
15 3	capsule	imipramine pamoate (75)	dextromethorphan hydrobromide (30)	
4	capsule	imipramine pamoate (125)	dextromethorphan hydrobromide (30)	
20 5	tablet	imipramine hydrochloride (50)	dextromethorphan hydrobromide (30)	
25 6	intramuscular injection	imipramine hydrochloride (100)	dextromethorphan hydrobromide (30)	
7	tablet	amoxapine (50)	dextromethorphan hydrobromide (30)	
30 8	tablet	desipramine hydrochloride (100)	dextromethorphan hydrobromide (30)	
9	tablet	amitriptyline hydrochloride (25)	dextromethorphan hydrobromide (30)	perphenazine (2)
35 10	tablet	amitriptyline hydrochloride (25)	dextromethorphan hydrobromide (30)	chlordiazepoxide (10)
40 11	capsule	doxepin hydrochloride (25)	dextromethorphan hydrobromide (30)	
12	capsule	nortriptyline hydrochloride (25)	dextromethorphan hydrobromide (30)	
45 13	tablet	amitriptyline hydrochloride (75)	dextromethorphan hydrobromide (30)	

<u>Example</u>	<u>Dosage Form</u>	<u>Antidepressant Drug (mg)</u>	<u>Nontoxic NMDA Receptor Blocker (mg)</u>	<u>Active Additional Component(s) (mg)</u>	
5	14	intramuscular injection	amitriptyline hydrochloride (20)	dextromethorphan hydrobromide (30)	
	15	capsule	trimipramine maleate (25)	dextromethorphan hydrobromide (30)	
10	16	tablet	fluoxetine hydrochloride (10)	dextromethorphan hydrobromide (30)	
	17	tablet	sertraline hydrochloride (50)	dextromethorphan hydrobromide (30)	
15	18	tablet	paroxetine hydrochloride (20)	dextromethorphan hydrobromide (30)	
	19	tablet	maprotiline hydrochloride (50)	dextromethorphan hydrobromide (30)	
	20	tablet	trazodone hydrochloride (50)	dextromethorphan hydrobromide (30)	
25	21	tablet	bupropion hydrochloride (100)	dextromethorphan hydrobromide (30)	
	22	tablet	benactyzine hydrochloride (1)	dextromethorphan hydrobromide (30)	meprobamate (400)
30	23	tablet	imipramine hydrochloride (25)	dextrophan hydrobromide (30)	
	24	tablet	fluoxetine hydrochloride (10)	dextrophan hydrobromide (30)	
	25	tablet	imipramine hydrochloride (25)	amantadine (30)	
40	26	tablet	fluoxetine hydrochloride (20)	amantadine (30)	
	27	tablet	imipramine hydrochloride (25)	memantine (30)	
45	28	tablet	fluoxetine hydrochloride (25)	memantine (30)	

<u>Example</u>	<u>Dosage Form</u>	<u>Antidepressant Drug (mg)</u>	<u>Nontoxic NMDA Receptor Blocker (mg)</u>	<u>Active Additional Component(s) (mg)</u>	
5	29	tablet	imipramine hydrochloride (25)	dextromethorphan hydrobromide (30)	acetaminophen (325)
	30	tablet	imipramine hydrochloride (25)	dextromethorphan hydrobromide (30)	aspirin (325)
10	31	tablet	imipramine hydrochloride (25)	dextromethorphan hydrobromide (30)	ibuprofen (325)
	32	tablet	fluoxetine hydrochloride (10)	dextromethorphan hydrobromide (30)	acetaminophen (325)
15	33	tablet	fluoxetine hydrochloride (10)	dextromethorphan hydrobromide (30)	aspirin (325)
	34	tablet	fluoxetine hydrochloride (10)	dextromethorphan hydrobromide (30)	ibuprofen (325)
	35	tablet	imipramine hydrochloride (25)	dextrorphan hydrobromide (30)	acetaminophen (325)
25	36	tablet	imipramine hydrochloride (25)	dextrorphan hydrobromide (30)	aspirin (325)
	37	tablet	imipramine hydrochloride (25)	amantadine (30)	acetaminophen (325)
30	38	tablet	fluoxetine hydrochloride (70)	amantadine (30)	aspirin (325)
	39	tablet	imipramine hydrochloride (25)	memantine (30)	acetaminophen (325)
	40	tablet	imipramine hydrochloride (25)	memantine (30)	ibuprofen (325)
40	41	tablet	phenelzine sulfate (15)	amantadine (30)	
	42	tablet	phenelzine sulfate (15)	memantine (30)	
45	43	tablet	isocarboxazid (30)	amantadine (30)	

<u>Example</u>	<u>Dosage Form</u>	<u>Antidepressant Drug (mg)</u>	<u>Nontoxic NMDA Receptor Blocker (mg)</u>	<u>Active Additional Component(s) (mg)</u>
5 44	tablet	isocarboxazid (30)	memantine (30)	
45	tablet	tranylcypromine sulfate (30)	amantadine (30)	
10 46	tablet	tranylcypromine sulfate (30)	memantine (30)	

15 In each of these dosage units, the nontoxic NMDA receptor antagonist dextromethorphan hydrobromide significantly potentiates the neuropathic pain-alleviating activity of the antidepressant component(s).

WHAT IS CLAIMED IS:

1. A therapeutic composition comprising at least one antidepressant, in an amount sufficient to alleviate neuropathic pain and at least one nontoxic N-methyl-D-aspartate receptor antagonist in an amount sufficient to potentiate the neuropathic pain-alleviating activity of the antidepressant.
2. The therapeutic composition of Claim 1 wherein the antidepressant is at least one member selected from the group consisting of tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, serotonin uptake inhibitors, bupropion hydrochloride and benactyzine hydrochloride.
3. The therapeutic composition of Claim 2 wherein the tricyclic antidepressant is selected from the group consisting of imipramine hydrochloride, imipramine pamoate, 2-chloroimipramine, amitriptyline hydrochloride, amoxapine, desipramine hydrochloride, doxepin hydrochloride, protriptyline hydrochloride, trimipramine maleate, nortriptyline hydrochloride and clomipramine hydrochloride.
4. The therapeutic composition of Claim 2 wherein the tetracyclic antidepressant is maprotiline hydrochloride.
5. The therapeutic composition of Claim 2 wherein the monoamine oxidase inhibitor is selected from the group consisting of phenelzine sulfate, isocarboxazid and tranylcypromine sulfate.
6. The therapeutic composition of Claim 2 wherein the serotonin uptake inhibitor is selected from the group consisting of paroxetine hydrochloride, fluoxetine hydrochloride, trazodone hydrochloride, citalopram, cis-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine, trans-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and aryloxy indanamine.

7. The therapeutic composition of Claim 1 containing a therapeutically effective amount of at least one other pharmacologically active substance.
8. The therapeutic composition of Claim 7 wherein the other pharmacologically active substance is selected from the group consisting of antianxiety agents, antipsychotic agents, non-narcotic analgesics and narcotic analgesics.
9. The therapeutic composition of Claim 8 wherein the antianxiety agent is selected from the group consisting of meprobamate and chlordiazepoxide.
10. The therapeutic composition of Claim 8 wherein the antipsychotic agent is perphenazine.
11. The therapeutic composition of Claim 8 wherein the non-narcotic analgesic is selected from the group consisting of tramadol, acetaminophen, aspirin, diclofenac, diflusal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.
12. The therapeutic composition of Claim 8 wherein the narcotic analgesic is selected from the group consisting of codeine, dihydrocodeine, hydrocodone, levorphanol, morphine, and oxycodone.
13. The therapeutic composition of Claim 1 wherein the nontoxic NMDA receptor blocker is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof, except that in the case of dextrorphan or salt thereof, the antidepressant is other than of the monoamine oxidase inhibitor type.

25

14. A method of alleviating neuropathic pain which comprises administering to a mammal exhibiting neuropathic pain at least one antidepressant in an amount sufficient to alleviate neuropathic pain and at least one nontoxic N-methyl-D-aspartate receptor antagonist in an amount sufficient to potentiate the neuropathic pain-alleviating activity of the antidepressant.

15. The method of Claim 14 wherein the antidepressant is at least one member selected from the group consisting of tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, serotonin uptake inhibitors, bupropion hydrochloride and benactyzine hydrochloride.

16. The method of Claim 15 wherein the tricyclic antidepressant is selected from the group consisting of imipramine hydrochloride, imipramine pamoate, 2-chloroimipramine, amitriptyline hydrochloride, amoxapine, desipramine hydrochloride, doxepin hydrochloride, protriptyline hydrochloride, trimipramine maleate, nortriptyline hydrochloride and clomipramine hydrochloride.

17. The method of Claim 15 wherein the tetracyclic antidepressant is maprotiline hydrochloride.

18. The method of Claim 15 wherein the monoamine oxidase inhibitor is selected from the group consisting of phenelzine sulfate, isocarboxazid and tranylcypromine sulfate.

19. The method of Claim 15 wherein the serotonin uptake inhibitor is selected from the group consisting of paroxetine hydrochloride, fluoxetine hydrochloride, trazodone hydrochloride, citalopram, cis-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine trans-isomeric derivative of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine, and aryloxy indanamine.

20. The method of Claim 14 wherein the nontoxic NMDA receptor blocker is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof, except that in the case of dextromethorphan, dextrorphan or salt thereof, the antidepressant is other than of the monoamine oxidase inhibitor type.
- 5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/09253

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K31/645 A61K31/485 A61K31/42 A61K31/135 A61K31/55
 A61K31/495

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 10815 A (FROME BRUCE M) 27 March 1997 see page 1, paragraph 2 see page 11; claims 1-3,5 see page 20-24 ---	1-3,7, 14-16
X	WO 96 09044 A (SMITH R.A.) 28 March 1996 see page 2, line 20-28; claims 1,4 see page 13, paragraph 3 see page 21, line 29-30; example 4 --- -/--	1-3,6, 13-16, 19,20

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
---	---

Date of the actual completion of the international search	Date of mailing of the international search report
27 August 1998	03/09/1998

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Kanbier, D
--	--------------------------------------

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/09253

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40095 A (HARRIS RICHARD Y) 19 December 1996	1-3,7,8, 11, 13-16,20
A	see page 1, line 7-8 see page 5, line 6-8 see page 8, line 36 - page 9, line 2 see page 9, line 18-19 ----	5,18
X	WO 96 27375 A (ALGOS PHARM CORP) 12 September 1996 see page 3, line 7-12; claims 1,5-10,24-27 see page 7, line 3-13 ----	1-3, 13-16,20
X	EP 0 627 434 A (SUMITOMO PHARMA) 7 December 1994 see page 3, line 1-11 ----	1,7,8,14
X	EP 0 658 539 A (LILLY CO ELI) 21 June 1995 see page 5, line 46-54 ----	1,7,8,14
A	US 5 605 911 A (WASHINGTON UNIVERSITY) 25 February 1997 see column 5, line 37-55; claim 8 see column 6, line 42-50; table 2 see column 6, line 64; example 4 see column 12, line 26-50 see column 16, line 1-30 ----	1-20
A	EP 0 615 749 A (UNIV VIRGINIA COMMONWEALTH) 21 September 1994 see column 1, line 27-58 see column 7, line 45-58; claims 1-3,5-8,10 -----	1-3,7,8, 11, 13-16,20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/09253

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 14-20
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
SEE FURTHER INFORMATION PCT/ISA/210 CONTINUATION
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 98 /09253

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds which are theoretically defined by the expressions "antidepressant" and "N-methyl-D-aspartate receptor antagonist" in claims 1 and 14, "pharmaceutically active substance" in claim 7, and "antianxiety agent", "antipsychotic agent" and "analgesic" in claim 8, the search has been restricted for economic reasons. The search was limited to the compounds cited in the examples and in claims 2-6, 9-13 and 15-20.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09253

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 9710815	A	27-03-1997	NONE	
WO 9609044	A	28-03-1996	AU 8071894 A EP 0788359 A JP 10505864 T	09-04-1996 13-08-1997 09-06-1998
WO 9640095	A	19-12-1996	US 5679715 A EP 0833623 A	21-10-1997 08-04-1998
WO 9627375	A	12-09-1996	AU 5090796 A CA 2213842 A EP 0820288 A	23-09-1996 12-09-1996 28-01-1998
EP 0627434	A	07-12-1994	CN 1098722 A JP 7002855 A US 5719152 A	15-02-1995 06-01-1995 17-02-1998
EP 0658539	A	21-06-1995	US 5576323 A AU 676781 B AU 7915194 A BR 9404809 A CN 1108240 A CZ 9402947 A FI 945704 A HU 69181 A JP 7267908 A NO 944578 A NZ 270009 A PL 306038 A ZA 9409405 A	19-11-1996 20-03-1997 08-06-1995 01-08-1995 13-09-1995 13-12-1995 04-06-1995 28-08-1995 17-10-1995 06-06-1995 29-01-1997 12-06-1995 28-05-1996
US 5605911	A	25-02-1997	NONE	
EP 0615749	A	21-09-1994	US 5352683 A CA 2115792 A JP 7002671 A US 5502058 A	04-10-1994 06-09-1994 06-01-1995 26-03-1996